Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of ADOC.PA is 14 and suggests 136% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell